Psoriasis Causes Significant Economic Burden to Patients
Authors:
Open Access
- 28 May 2014
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 4 (1) , 115-124
Abstract
Introduction Psoriasis results in expenses to patients from many cost sources. Psoriasis treatments may result in considerable time and traveling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the multidimensional economic burden of psoriasis to patients. Methods The study was based on 232 Finnish patients with psoriasis or psoriatic arthritis visiting a tertiary level dermatological clinic during a 1-year study period between October 1, 2009 and September 30, 2010. The data were based on a patient questionnaire, clinical data from the medical records and reimbursement data from the Finnish Social Insurance Institution. Item costs were based on true costs charged from the patients and all time cost estimates were based on the Human Capital Approach method. Results 199 patients with psoriasis and 33 with psoriatic arthritis were included in the study. Total costs were higher for patients receiving traditional systemic medications or phototherapy than those not receiving such treatment. Travel costs and travel time costs accounted for more than 60% of the costs of phototherapy. Skin care at home was time consuming and thus caused significant burden to patients. The majority of the visit costs arose from hospital visits and only a small proportion were attributed to visiting primary health care providers. Conclusion Visit charges and other patient co-payments were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and lost time comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.Keywords
This publication has 29 references indexed in Scilit:
- Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with ArthritisDermatology and Therapy, 2013
- The Burden of Moderate to Severe PsoriasisPharmacoEconomics, 2012
- Psoriasis: an epidemiological evaluation of disease burden in 590 patientsJournal of the European Academy of Dermatology and Venereology, 2010
- Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United StatesJournal of Dermatological Treatment, 2010
- One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinicJournal of the American Academy of Dermatology, 2008
- Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center studyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II)Journal of the European Academy of Dermatology and Venereology, 2006
- Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness StudyDermatology, 2006
- How patients experience psoriasis: results from a European surveyJournal of the European Academy of Dermatology and Venereology, 2005
- Epidemiology of psoriatic arthritis in the population of the United StatesJournal of the American Academy of Dermatology, 2005